Syncona Limited NPV (SYNC)

Sector:

Investment Firms

Index:

FTSE 250

220.50p
   
  • Change Today:
    -1.50p
  • 52 Week High: 294.00
  • 52 Week Low: 213.50
  • Currency: UK Pounds
  • Shares Issued: 663.67m
  • Volume: 236,934
  • Market Cap: £1,463.38m
  • RiskGrade: 291
  • Beta: 0.71

Syncona's Freeline Therapeutics upbeat on haemophilia trial data

By Josh White

Date: Monday 08 Jul 2019

LONDON (ShareCast) - (Sharecast News) - Healthcare company Syncona announced on Monday that its portfolio company, Freeline Therapeutics, has presented 52-week data from the first cohort of two patients in the ongoing 'B-AMAZE FLT180a' phase 1 and 2 trial in haemophilia B.
The FTSE 250 company said the Freeline haemophilia B programme, 'FLT180a', used the 'AAVS3' capsid and a gain of function variant of human factor IX (FIX).

Freeline said the therapy was in a phase 1 and 2 trial known as 'B-AMAZE', with the goal of normalising FIX activity in patients with moderate and severe haemophilia B.

It said it presented data from the first cohort of two patients who were treated with the lowest study dose.

Over the 12 months since infusion, both patients' liver enzymes remained within the normal range at all time points and the patients' transgene expression was stable, with Factor IX levels of 40.5±4.5% at week 52, assessed by the one stage clotting assay using the 'SynthASil' reagent.

Following treatment, Freeline said both patients were free of spontaneous bleeding episodes and did not require any Factor IX supplementation.

It said it as continuing to enrol patients in the B-AMAZE trial, with the goal of optimising the dose to express Factor IX in the normal range of 50-150%, which would reportedly free patients from the symptoms of the disease.

"We are pleased to report updated data on the first two patients in our haemophilia B trial," said Freeline executive chairman Chris Hollowood.

"The results provide early validation for the potential durability and stability of our therapy at the lowest dose cohort.

"We continue to progress dose optimisation in additional patients and look forward to providing a further update as we seek to develop a functional cure for people with Haemophilia B."

Hollowood said the company believed there was a "significant opportunity" for Freeline's "highly efficient" capsid and manufacturing platform to offer gene therapies that substantially improve patients' lives in a wide range of chronic systemic diseases.

"We are seeking to leverage this same platform across Haemophilia A and B, Fabry and Gaucher Diseases, and ultimately into non-monogenic disorders."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

SYNC Market Data

Currency UK Pounds
Share Price 220.50p
Change Today -1.50p
% Change -0.68 %
52 Week High 294.00
52 Week Low 213.50
Volume 236,934
Shares Issued 663.67m
Market Cap £1,463.38m
Beta 0.71
RiskGrade 291

SYNC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
92.24% below the sector average92.24% below the sector average92.24% below the sector average92.24% below the sector average92.24% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
37.47% below the sector average37.47% below the sector average37.47% below the sector average37.47% below the sector average37.47% below the sector average
Income
Market averageMarket averageMarket averageMarket averageMarket average
96.08% below the sector average96.08% below the sector average96.08% below the sector average96.08% below the sector average96.08% below the sector average
Growth
Market averageMarket averageMarket averageMarket averageMarket average
41.42% above the sector average41.42% above the sector average41.42% above the sector average41.42% above the sector average41.42% above the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

SYNC Dividends

  Latest Previous
  Final Final
Ex-Div 20-Jun-19 21-Jun-18
Paid 29-Jul-19 30-Jul-18
Amount 2.30p 2.30p

Trades for 05-Dec-2019

Time Volume / Share Price
16:35 43,536 @ 220.50p
16:29 395 @ 221.50p
16:29 346 @ 221.50p
16:29 529 @ 221.50p
16:29 433 @ 221.50p

Top of Page